Abcam Plc (ABC) - Financial and Strategic SWOT Analysis Review

Abcam Plc (ABC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description - A detailed description of the company’s operations and business divisions.
Corporate strategy - Analyst’s summarization of the company’s business strategy.
SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history - Progression of key events associated with the company.
Major products and services - A list of major products, services and brands of the company.
Key competitors - A list of key competitors to the company.
Key employees - A list of the key executives of the company.
Executive biographies - A brief summary of the executives’ employment history.
Key operational heads - A list of personnel heading key departments/functions.
Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Abcam Plc (Abcam) is a supplier of life science research tools for analysis of living cells at molecular level to understand a wide range of disease conditions. The company develops and markets antibodies and other related products. Its product portfolio includes primary antibodies, secondary antibodies, immunoassay kits and reagents, cell and tissue imaging tools, cellular and biochemical assays, proteins and peptides, proteomics tools, activators, agonists, antagonists and inhibitors, lysates, and multiplex miRNA assay. Abcam’s products serve life science researchers to identify proteins for life sciences and veterinary sciences. The company distributes its products in the Americas, Europe, Asia-Pacific, and other countries. Abcam is headquartered in Cambridge, Cambridgeshire, the UK.

Abcam Plc Key Recent Developments

Nov 09, 2022: NanoString and Abcam expand collaboration to advance spatial multiomics research
Sep 12, 2022: ABCAM : Appointment of Non-Executive Director
Sep 01, 2022: Abcam to participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Apr 04, 2022: ABCAM Announces Publication of 2021 Annual Report and Accounts and Notice of Annual General Meeting

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Section 1 - About the Company

Abcam Plc - Key Facts
Abcam Plc - Key Employees
Abcam Plc - Key Employee Biographies
Abcam Plc - Major Products and Services
Abcam Plc - History
Abcam Plc - Company Statement
Abcam Plc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

Section 2 - Company Analysis

Company Overview
Abcam Plc - Business Description
Other Break-up: BioVision
Performance
Other Break-up: Catalogue Product
Overview
Performance
Other Break-up: Custom Products and Licensing
Overview
Performance
Geographical Segment: China
Performance
Geographical Segment: EMEA
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Rest of Asia Pacific
Performance
Geographical Segment: The Americas
Performance
R&D Overview
Abcam Plc - Corporate Strategy
Abcam Plc - SWOT Analysis
SWOT Analysis - Overview
Abcam Plc - Strengths
Abcam Plc - Weaknesses
Abcam Plc - Opportunities
Abcam Plc - Threats
Abcam Plc - Key Competitors

Section 3 - Company Financial Ratios

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

Section 4 - Company’s Lifesciences Financial Deals and Alliances

Abcam Plc, Medical Equipment, Deals By Year, 2017 to YTD 2023
Abcam Plc, Medical Equipment, Deals By Type, 2017 to YTD 2023
Abcam Plc, Recent Deals Summary

Section 5 - Company’s Recent Developments

Nov 09, 2022: NanoString and Abcam expand collaboration to advance spatial multiomics research
Sep 12, 2022: ABCAM : Appointment of Non-Executive Director
Sep 01, 2022: Abcam to participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Apr 04, 2022: ABCAM Announces Publication of 2021 Annual Report and Accounts and Notice of Annual General Meeting
Mar 25, 2022: Abcam the most awarded company at 2022 industry awards
Mar 14, 2022: Abcam: Results for the period ended 31 December 2021
Jan 04, 2022: Alamar Biosciences partners with Abcam to drive understanding of the human proteome

Section 6 - Appendix